Stockreport

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Praxis Precision Medicines, Inc.  (PRAX) 
PDF  Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively Continued strong [Read more]